TY - JOUR
T1 - Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio
AU - Burns, Tammy
AU - Maciejewski, Stephanie R.
AU - Hamilton, William R.
AU - Zheng, Margaret
AU - Mooss, Aryan N.
AU - Hilleman, Daniel E.
PY - 2007/5/1
Y1 - 2007/5/1
N2 - Study Objectives. To determine the baseline arachidonic acid:eicosapentaenoic acid (AA:EPA) ratio in patients with coronary artery disease and healthy subjects, and whether supplementation of omega-3 fatty acids, administered as fish oil capsules, affects this ratio. Design. Prospective, open-label trial. Setting. University-affiliated cardiology clinic. Subjects. Thirty patients with stable coronary artery disease (CAD) and 30 healthy subjects. Intervention. All participants received omega-3 fatty acids 1.5 g/day for 4 weeks, followed by 3 g/day for an additional 4 weeks. Measurements and Main Results. For each participant, a lipid profile was determined at baseline and after 4 weeks of treatment with each dose. Other laboratory results analyzed were serum AA:EPA ratios, high-sensitivity C-reactive protein (hs-CRP) levels, and blood glucose levels. Mean ± SD baseline AA:EPA ratios were 39.6 ± 19.0 in healthy subjects and 23.7 ± 12.5 in patients with CAD. These ratios decreased significantly in both groups after treatment with 1.5 g/day of omega-3 fatty acids: 9.0 ± 4.2 in healthy subjects and 10.3 ± 8.8 in patients with CAD. After treatment with 3 g/day, the ratios were further reduced: 5.1 ± 3.2 in healthy subjects and 4.9 ± 2.6 in patients with CAD. Supplementation with omega-3 fatty acids did not significantly affect hs-CRP, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or blood glucose levels. Triglyceride levels were not reduced in patients with CAD but were significantly decreased in healthy subjects (by 20% decrease with omega-3 fatty acids 1.5 g/day and by 32% decrease with 3 g/day). Conclusion. Treatment with omega-3 fatty acids significantly reduced AA:EPA ratios in both healthy subjects and in patients with stable CAD. The treatment had no effect on hs-CRP levels in either group, and it reduced triglyceride levels in healthy subjects but not in patients with CAD.
AB - Study Objectives. To determine the baseline arachidonic acid:eicosapentaenoic acid (AA:EPA) ratio in patients with coronary artery disease and healthy subjects, and whether supplementation of omega-3 fatty acids, administered as fish oil capsules, affects this ratio. Design. Prospective, open-label trial. Setting. University-affiliated cardiology clinic. Subjects. Thirty patients with stable coronary artery disease (CAD) and 30 healthy subjects. Intervention. All participants received omega-3 fatty acids 1.5 g/day for 4 weeks, followed by 3 g/day for an additional 4 weeks. Measurements and Main Results. For each participant, a lipid profile was determined at baseline and after 4 weeks of treatment with each dose. Other laboratory results analyzed were serum AA:EPA ratios, high-sensitivity C-reactive protein (hs-CRP) levels, and blood glucose levels. Mean ± SD baseline AA:EPA ratios were 39.6 ± 19.0 in healthy subjects and 23.7 ± 12.5 in patients with CAD. These ratios decreased significantly in both groups after treatment with 1.5 g/day of omega-3 fatty acids: 9.0 ± 4.2 in healthy subjects and 10.3 ± 8.8 in patients with CAD. After treatment with 3 g/day, the ratios were further reduced: 5.1 ± 3.2 in healthy subjects and 4.9 ± 2.6 in patients with CAD. Supplementation with omega-3 fatty acids did not significantly affect hs-CRP, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or blood glucose levels. Triglyceride levels were not reduced in patients with CAD but were significantly decreased in healthy subjects (by 20% decrease with omega-3 fatty acids 1.5 g/day and by 32% decrease with 3 g/day). Conclusion. Treatment with omega-3 fatty acids significantly reduced AA:EPA ratios in both healthy subjects and in patients with stable CAD. The treatment had no effect on hs-CRP levels in either group, and it reduced triglyceride levels in healthy subjects but not in patients with CAD.
UR - http://www.scopus.com/inward/record.url?scp=34247850808&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247850808&partnerID=8YFLogxK
U2 - 10.1592/phco.27.5.633
DO - 10.1592/phco.27.5.633
M3 - Article
C2 - 17461697
AN - SCOPUS:34247850808
VL - 27
SP - 633
EP - 638
JO - Pharmacotherapy
JF - Pharmacotherapy
SN - 0277-0008
IS - 5
ER -